Protagonist Therapeutics, Inc
PN-881
Resolved
7days ago
Phase 1 readout · Jun 30, 2026
What's at stake
Phase 1 trial results for PN-881 in its lead indication are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“The Company expects its Phase 1 study of PN-881 to be complete by mid-2026, informing subsequent clinical development plans.”